Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > BUSINESS
BUSINESS
- Otsuka Holdings Weighs Staff Realignment as Abilify Patent Expiry Looms
February 16, 2015
- Merck Serono to Independently Promote Erbitux from May
February 16, 2015
- Otsuka Holdings Promotes Vice Chairman Ichiro Otsuka to Chairman on March 27
February 16, 2015
- Meiji Seika Pharma Completes Acquisition of Outstanding Shares of Medreich
February 16, 2015
- Antithrombotic Agent Sales Up 7.4% in 2014 on Buoyant Plavix, Xarelto: IMS
February 13, 2015
- GSK Eyes Transfer of Oncology Teams to Novartis from March
February 13, 2015
- Japan Pharma Market Grows 1.4% in 2014, Plavix Retains Crown in Sales Ranking: IMS
February 13, 2015
- AbbVie Files NDA for Chronic Hepatitis C Treatment in Japan
February 13, 2015
- Otsuka Pharma Pres. Iwamoto Dies at 54, Holding Firm CEO to Take Over
February 12, 2015
- Hypertension Most Commonly Treated Disease in Japan: Survey
February 12, 2015
- JCR Begins PI Study of Biosimilar for Fabry’s Disease Therapy
February 12, 2015
- Ixazomib, Successor to Velcade, Improved PFS in Interim Analysis of PIII Study: Takeda
February 12, 2015
- Once-Monthly Oral Ibandronate Filed for Approval in Japan: Chugai, Taisho
February 12, 2015
- Daiichi Sankyo Launches Edoxaban in US
February 10, 2015
- Sandoz K.K. Names Mr Hasegawa as New President
February 10, 2015
- Takeda Cuts Costs of 19.5 Billion Yen by December 2014
February 9, 2015
- Ethical Drug Sales Up 2.5% in December: Crecon Report
February 9, 2015
- Astellas to Set Up New Panel on Global Management
February 6, 2015
- Eisai Discloses Option Rights for AD Treatment under Deal with Biogen Idec
February 6, 2015
- Novartis Pharma Should Take Suspension Order Serious: Mr Tsuchiya of JSHP
February 5, 2015
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…